What You Should Know:
– The Federal Trade Commission (FTC) has reached a settlement with Southern Health Solutions, Inc., operating as Next Medical and NextMed, and its founders Robert Epstein and CEO Frank Leonardo III.
–…
Continue Reading
Sami Inkinen, co-founder and CEO of Virta Health
On the heels of Weight Watchers’ recent bankruptcy filing, the conversation around the future of the weight loss industry has intensified. While many point to the rise…
Continue Reading
Patent Monopolies Drive Record Profits
Novo Nordisk and Eli Lilly have transformed GLP-1 receptor agonists into unprecedented profit machines. These blockbuster drugs, approved for diabetes and weight loss, generate billions while leaving many patients unable…
What You Should Know:
– PatchMD, a pioneer in transdermal nutrient delivery, has unveiled its new GLP-1 Support Patch Collection, designed to provide essential support for individuals using GLP-1 receptor agonist medications such as Ozempic,…
Continue Reading
Following Hims & Hers’ Super Bowl ad for its weight loss product, a debate has emerged over the safety of compounded GLP-1s for patients.
Compounded GLP-1s are custom-made by compounding pharmacies and include the same…
Continue Reading
DarioHealth, a digital chronic condition management platform, announced it expanded its GLP-1 offering with prescribing capabilities, a move the company said will help it capture a larger share of the weight-loss market space.The company…
Continue Reading
The Unprecedented Rise in Medicaid’s Diabetes Drug Spending
Introduction to the Crisis
Medicaid faces a staggering projection of $29.9 billion in expenditure for type 2 diabetes and weight loss medications, according to a recent report from…
Top News
Elevance Health’s Anthem Blue Cross Blue Shield accuses physicians of falsifying patient medical records with the intention of getting the insurer to pay for improper prescribing of the diabetes drug Ozempic for weight…
Continue Reading
What You Should Know:
– A new study suggests that a weekly treatment with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may significantly reduce the risk of kidney failure and other complications in patients with…
Continue Reading
As the nation grapples with a GLP-1 shortage, Hims & Hers is looking to improve access by making compounded GLP-1s available on its platform starting at $199 a month, the company announced Monday.
The San…
Continue Reading
